Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics updates investor presentation for IKT-001 PAH program

Neutral Impact 2 of 5 other Written later

Inhibikase Therapeutics furnished an updated corporate presentation dated September 2026 for use in meetings with investors and analysts. The filing is a Regulation FD disclosure with no new financial results, guidance, or transaction terms; the presentation restates the company's IKT-001 Phase 3 IMPROVE-PAH development plan and timelines.

Key points

  • Updated corporate presentation dated September 2026 furnished as Exhibit 99.1, issued September 8, 2026
  • Presentation describes single pivotal Phase 3 IMPROVE-PAH study enrolling across 26 countries and 46 active sites, with a target of about 180 planned sites
  • Projected timelines include interim safety readout in 1H 2027, unblinded PVR readout in mid 2028, and topline 6MWD readout in mid 2029
  • Filing states cash runway through Phase 3 Part B topline data readout, assuming full and timely exercise of Series A and B Warrants

The filing

CompanyInhibikase Therapeutics, Inc. (IKT)
Form8-K, current report
Filed with the SECSep 8, 2026, 4:41 PM ET
Accession number0001193125-26-385293

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.